View Future GrowthEuroespes 과거 순이익 실적과거 기준 점검 0/6Euroespes 의 수입은 연평균 -519.8%의 비율로 감소해 온 반면, Life Sciences 산업은 연평균 4.9%의 비율로 증가했습니다. 매출은 연평균 0.09%의 비율로 증가해 왔습니다.핵심 정보-519.80%순이익 성장률-565.08%주당순이익(EPS) 성장률Life Sciences 산업 성장률26.83%매출 성장률0.085%자기자본이익률-18.34%순이익률-29.49%최근 순이익 업데이트31 Dec 2022최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updatesNew Risk • Nov 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 13% per year over the past 5 years. Market cap is less than US$10m (€3.67m market cap, or US$3.99m). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Revenue is less than US$5m (€3.9m revenue, or US$4.2m).New Risk • Jul 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 4.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€1.4m free cash flow). Earnings have declined by 13% per year over the past 5 years. Market cap is less than US$10m (€3.46m market cap, or US$3.85m). Minor Risks Share price has been volatile over the past 3 months (4.6% average weekly change). Revenue is less than US$5m (€3.9m revenue, or US$4.3m).New Risk • Jun 11New major risk - Revenue and earnings growthEarnings have declined by 24% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€1.4m free cash flow). Earnings have declined by 24% per year over the past 5 years. Market cap is less than US$10m (€3.85m market cap, or US$4.14m). Minor Risk Revenue is less than US$5m (€3.9m revenue, or US$4.1m).Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.분석 기사 • Nov 11Would Euroespes (BME:EEP) Be Better Off With Less Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...분석 기사 • May 10Here's Why Euroespes (BME:EEP) Can Afford Some DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Is New 90 Day High Low • Jan 13New 90-day high: €0.48The company is up 2.0% from its price of €0.47 on 14 October 2020. The Spanish market is up 18% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Life Sciences industry, which is also up 2.0% over the same period.Is New 90 Day High Low • Dec 23New 90-day low: €0.37The company is down 24% from its price of €0.48 on 24 September 2020. The Spanish market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 3.0% over the same period.Is New 90 Day High Low • Dec 02New 90-day low: €0.40The company is down 17% from its price of €0.48 on 03 September 2020. The Spanish market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 1.0% over the same period.매출 및 비용 세부 내역Euroespes가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이BME:EEP 매출, 비용 및 순이익 (EUR Millions)날짜매출순이익일반관리비연구개발비31 Dec 224-11030 Sep 224-10030 Jun 22400031 Mar 22400031 Dec 21400030 Sep 21400030 Jun 21300031 Mar 21300031 Dec 20300030 Sep 203-10030 Jun 202-10031 Mar 202-10031 Dec 193-10030 Sep 193-10030 Jun 193-10031 Mar 193-10031 Dec 18300030 Sep 18300030 Jun 18300031 Mar 18300031 Dec 17300030 Sep 17400030 Jun 17400031 Mar 17400031 Dec 16300030 Jun 16300031 Mar 16300031 Dec 15300030 Jun 15300031 Mar 15300031 Dec 14300031 Dec 133000양질의 수익: EEP 은(는) 현재 수익성이 없습니다.이익 마진 증가: EEP는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 지난 5년 동안 EEP의 연간 수익 성장률이 양(+)이었는지 판단하기에 데이터가 부족합니다.성장 가속화: 현재 수익성이 없어 지난 1년간 EEP의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: EEP은 수익성이 없어 지난 해 수익 성장률을 Life Sciences 업계(11.5%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: EEP는 현재 수익성이 없으므로 자본 수익률이 음수(-18.34%)입니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/02/28 10:23종가2023/12/01 00:00수익2022/12/31연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Euroespes, S.A.는 0명의 분석가가 다루고 있습니다. 이 중 명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
New Risk • Nov 14New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 13% per year over the past 5 years. Market cap is less than US$10m (€3.67m market cap, or US$3.99m). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Revenue is less than US$5m (€3.9m revenue, or US$4.2m).
New Risk • Jul 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 4.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€1.4m free cash flow). Earnings have declined by 13% per year over the past 5 years. Market cap is less than US$10m (€3.46m market cap, or US$3.85m). Minor Risks Share price has been volatile over the past 3 months (4.6% average weekly change). Revenue is less than US$5m (€3.9m revenue, or US$4.3m).
New Risk • Jun 11New major risk - Revenue and earnings growthEarnings have declined by 24% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€1.4m free cash flow). Earnings have declined by 24% per year over the past 5 years. Market cap is less than US$10m (€3.85m market cap, or US$4.14m). Minor Risk Revenue is less than US$5m (€3.9m revenue, or US$4.1m).
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
분석 기사 • Nov 11Would Euroespes (BME:EEP) Be Better Off With Less Debt?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
분석 기사 • May 10Here's Why Euroespes (BME:EEP) Can Afford Some DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Is New 90 Day High Low • Jan 13New 90-day high: €0.48The company is up 2.0% from its price of €0.47 on 14 October 2020. The Spanish market is up 18% over the last 90 days, indicating the company underperformed over that time. However, its price trend is similar to the Life Sciences industry, which is also up 2.0% over the same period.
Is New 90 Day High Low • Dec 23New 90-day low: €0.37The company is down 24% from its price of €0.48 on 24 September 2020. The Spanish market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is up 3.0% over the same period.
Is New 90 Day High Low • Dec 02New 90-day low: €0.40The company is down 17% from its price of €0.48 on 03 September 2020. The Spanish market is up 15% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Life Sciences industry, which is down 1.0% over the same period.